Location of Repository

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over

By J. Shepherd, G. Rogers, R. Anderson, C. Main, J. Thomson-Coon, D. Hartwell, Z Liu, Emma Loveman, C.J. Green, M Pitt, K Stein, P. Harris, GK Frampton, M Smith, A. Takeda, A. Price, K. Welch and M Somerville

Abstract

OBJECTIVES: To assess the clinical and cost-effectiveness of inhaled corticosteroids (ICS) alone and ICS used in combination with a long-acting beta2 agonist (LABA) in the treatment of chronic asthma in adults and children aged over 12 years. DATA SOURCES: Major electronic bibliographic databases, e.g. MEDLINE and EMBASE, were searched up to February/March 2006 (and updated again in October 2006). REVIEW METHODS: A systematic review of clinical and cost-effectiveness studies was conducted. Cost comparison and cost-consequence analyses were performed where appropriate. RESULTS: The assessment of clinical effectiveness was based on the 67 randomised controlled trials selected from the 5175 reports identified through the systematic literature search. The most frequently reported relevant outcomes were lung function, symptoms, use of rescue medication and adverse events. The trials varied considerably. In the trials that compared low-dose ICS versus ICS and high-dose ICS versus ICS, there were few significant differences in clinical effectiveness, although a few of the trials had assessed non-inferiority between the comparators rather than superiority. At doses of 400, 800 and 'high-level' doses of 1500 or 1600 microg/day, beclometasone dipropionate (BDP) appears to be the current cheapest ICS product both with the inclusion and exclusion of chlorofluorocarbon (CFC)-propelled products. A significant treatment benefit for combination ICS/LABA therapy across a range of outcomes compared with ICS alone was identified [when the ICS was double the accepted clinically equivalent dose of the ICS in the combination inhaler, and dry powder inhalers (DPIS) were used to deliver the drugs]. When a formoterol fumarate (FF)/salmeterol (SAL) combination inhaler and a budesonide (BUD)/FF combination inhaler were each compared with their constituent drugs delivered in separate inhalers, there were very few statistically significant differences between the treatments across the various efficacy outcomes and the rate of adverse events. Combination inhalers were more often cheaper than doubling the dose of ICS alone. However, the costs were highly variable and dependent on both the dose required and the preparation used in the trials. The estimated mean annual cost of FP/SAL combination varied from being 94 pounds cheaper to 109 pounds more expensive than the alternative of BUD at a higher dose. The BUD/FF combination varied from being 163 pounds cheaper to 66 pounds more expensive than the higher dose of either BUD or FP. When the combination inhalers were compared to each other, the results were mixed, with the FP/SAL combination significantly superior on some outcomes and the BUD/FF combination superior on others; however, meta-analysis showed that there were no significant differences between the two treatments in the rate of adverse events. Taking an ICS with a LABA as either of the two currently available combination products, FP/SAL and BUD/FF, is usually cheaper than taking the relevant constituent drugs in separate inhalers. At very high doses of BUD (1600 microg/day), however, the BUD/FF combination inhaler can be up to 156 pounds more expensive than having the same drugs in separate inhalers. In terms of the relative costs associated with taking one of the combination inhalers, at low dose (400 microg BUD or 200 microg FP/day) the cheapest combination inhaler is FP/SAL as a pressurised metered dose inhaler (pMDI) (Seretide Evohaler). However, this is only slightly cheaper than using BUD/FF as a DPI (Symbicort Turbohaler). At higher dose levels (800 microg BUD or 500 microg FP/day) FP/SAL as either pMDI aerosol (Seretide Evohaler) or a DPI (Seretide Accuhaler) is the cheapest combination product available, but again only slightly cheaper than the DPI BUD/FF combination (Symbicort Turbohaler). It should be highlighted, however, that the three head-to-head trials that compared the effects of FP/SAL with BUD/FF used the FP/SAL DPI combination inhaler, Seretide Accuhaler. CONCLUSIONS: The evidence indicates that there are few consistent significant differences in effects between the five ICS licensed for use in adults and adolescents over the age of 12 years, at either low or high dose. On average, BDP products currently tend to be the cheapest ICS available and tend to remain so as the daily ICS dose required increases. There is evidence that the addition of a LABA to an ICS is potentially more clinically effective than doubling the dose of ICS alone, although consistent significant differences between the two treatment strategies are not observed for all outcome measures. The cost differences between combination therapy compared with ICS monotherapy are highly variable and dependent on the dose required and the particular preparations used. For the combination therapies of ICS/LABA there are potential cost savings with the use of combination inhalers compared with separate inhalers, with few differences between the two treatment strategies in terms of effects. The only exception to this cost saving is with BUD/FF at doses higher than 1200 microg/day, where separate inhaler devices can become equivalent to or cheaper than combination inhalers. Neither of the two combination inhalers (FP/SAL or BUD/FF) is consistently superior in terms of treatment effect. A comparison of the costs associated with each combination therapy indicates that at low dose FP/SAL delivered via a pMDI is currently the cheapest combination inhaler but only marginally cheaper than BUD/FF delivered as a DPI. At higher doses, both the FP/SAL combination inhalers (PMDI and DPI) are marginally cheaper than BUD/FF (DPI). Future trials of treatment for chronic asthma should standardise the way in which outcome measures are defined and measured, with a greater focus on patient-centred outcomes. For informing future cost-utility and cost-effectiveness analyses from a UK NHS perspective, there is a need for longitudinal studies that comprehensively track the care pathways followed when people experience asthma exacerbations of different severity. Further research synthesis, quantifying the adverse effects of the different ICS, is required for treatment choices by patients and clinicians to be fully informed.<br/><br/

Topics: R1, RJ101, RZ
Year: 2008
OAI identifier: oai:eprints.soton.ac.uk:72886
Provided by: e-Prints Soton
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://dx.doi.org/10.3310/hta1... (external link)
  • Suggested articles

    Citations

    1. (2001). 1 Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease: a rapid and systematic
    2. (2000). 232comparison of four approaches. Respir Med
    3. A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate. doi
    4. (2000). A review by
    5. (2002). A study of the methods used to select review criteria for clinical audit. By Hearnshaw
    6. (2008). A systematic review and economic model of switching from nonglycopeptide to glycopeptide antibiotic prophylaxis for surgery.
    7. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. doi
    8. Agreement between a generic and disease-specific quality-of-life instrument: the 15D and the SGRQ in asthmatic patients.
    9. (2008). All rights reserved.No. 19 Clinical effectiveness and costeffectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic
    10. (2008). All rights reserved.No. 2 ‘Cut down to quit’ with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic doi
    11. (2008). All rights reserved.No. 34 A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies. By MacLehose
    12. (2008). All rights reserved.No. 4 A systematic review of the effectiveness and cost-effectiveness of neuroimaging assessments used to visualise the seizure focus in people with refractory epilepsy being considered for surgery. By Whiting doi
    13. (2008). All rights reserved.No. 5 A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines. By doi
    14. (2008). All rights reserved.Volume 9,
    15. (2001). Ann Allergy Asthma Immunol doi
    16. (2005). Are decisions using cost–utility analyses robust to choice of SF-36/SF-12 preference-based algorithm? Health Qual Life Outcomes doi
    17. (2008). Assessment reports published to date 376Health Technology Assessment
    18. authors would like to know your views about this report.
    19. Budesonide/ formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma – a randomized, double-blind trial. doi
    20. (2003). Comparison of directly elicited preferences to preferences derived from the SF-36 in adults with asthma. Med Decis Making doi
    21. Comparison of hydrofluoroalkane-beclomethasone dipropionate Autohaler with budesonide Turbuhaler in asthma control. doi
    22. Comparison of the standard gamble, rating scale, AQLQ and SF-36 for measuring quality of life in asthma. doi
    23. Control of airway inflammation maintained at a lower steroid dose with 100/50 µg of fluticasone propionate/ salmeterol. doi
    24. Development of the multi-attribute pediatric asthma health outcome measure (PAHOM).
    25. (2007). Estimating a preference-based single index from the Asthma Quality of Life Questionnaire (AQLQ).
    26. Extrafine beclomethasone dipropionate breath-actuated inhaler (400 muG/day) versus budesonide dry powder inhaler (800 muG/day) in asthma.
    27. (2003). Health related quality of life in individuals with asthma related symptoms. Respir Med doi
    28. (2003). How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical
    29. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. doi
    30. (2007). No. 1 Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation. By Dundar
    31. (2006). No. 1 The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. By Loveman E, doi
    32. One-year economic evaluation of intensive vs conventional patient education and supervision for selfmanagement of new asthmatic patients. Respir Med 1998;92:300–7. doi
    33. (2005). Relationship among sociodemographic factors, clinical conditions, and health-related quality of life: examining the EQ-5D in the US general population. Qual Life Res doi
    34. (2000). The combination of salmeterol and low-dose fluticasone versus higherdose fluticasone: an analysis of asthma exacerbations. doi
    35. (2006). The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin doi
    36. (1999). UK Population Norms for EQ-5D. Discussion Paper. University of York: Centre for Health Economics;
    37. (2008). View/download the appendices (1200 kbytes). Health Technology Assessment
    38. (2004). What is the best imaging strategy for acute stroke? By

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.